Revenue

Broadway star Morgan Dudley returns to the tech platform that discovered her, a high-stakes move for Stargaze's bid to reshape talent discovery.

Following a major clinical trial win, Kymera Therapeutics seeks $500M. We break down the high-stakes strategy behind funding a new era of medicine.

A junior miner's historic regulatory win in Oregon could set a new precedent for resource development, balancing economic promise with environmental rigor.

New clinical data reveals a breakthrough 'off-the-shelf' cell therapy that could treat severe autoimmune diseases by re-engineering cellular identity.

Latham Group hires building products veteran Sean Gadd to lead its next wave of growth. Can a playbook that dominated fiber cement convert the pool industry?

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

As it readies for a SPAC merger, quantum leader Infleqtion hires a top aerospace veteran to scale its sensing unit for defense and commercial markets.

Vapotherm partners with Flight Medical, launching the VentO2ux ventilator to challenge market giants and redefine emergency respiratory care in the US.

Global X's Bitcoin ETFs promise hefty semi-monthly payouts. But is this crypto-generated income a golden opportunity or a high-stakes volatility gamble?

When a 'living drug' for cancer fails, hope fades. A new biologic aims to repaint the target, giving patients' own immune cells a second chance to win.

NJBIZ honors Tevogen for its innovation, but can the biotech firm turn its ambitious multi-billion-dollar forecasts into reality? A deep dive.

Lifestyle experts are shaping your holiday shopping. We dissect the strategy behind curated gift guides, influencer endorsements, and the media firms driving them.

A food-tech firm's pivot from quiet operator to public force reveals a savvy digital strategy, a key US acquisition, and a plan to dominate the 'better-for-you' market.

A tech-enabled CRO enrolled 550+ oncology patients in six months, a feat that signals a major disruption to the slow, costly drug development process.

A Japanese EdTech firm is offering unlimited free English lessons in Brazil. Is this a savvy market capture or a high-risk gamble in a crowded space?

As consumer debt soars, a key advocacy group's new data-focused leadership could turn a powerful analytical lens on the role of healthcare and drug prices.

A cub’s rescue reveals more than a conservation win; it showcases China's massive investment in 'ecological civilization' as a core economic strategy.

WEP's deployment of 700 inspection systems in Missouri showcases its execution, but can it leverage this win in a competitive multi-billion dollar market?

A 40-year-old San Antonio dermatology group joins a corporate network, highlighting a national trend. What does this mean for local patients and physicians?

Wrapbook's acquisition of scheduling platform Cinapse promises to end decades of fragmented workflows, creating a single system for planning and payroll.